Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes

Shizuo Narimatsu, Chie Takemi, Daisuke Tsuzuki, Hiroyuki Kataoka, Shigeo Yamamoto, Noriaki Shimada, Satoshi Suzuki, Tetsuo Satoh, Urs A. Meyer, Frank J. Gonzalez

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A new HPLC method was developed using a chiral column to efficiently separate four 1″-hydroxybufuralol (1″-OH-BF) diastereomers that are major metabolites of bufuralol (BF). Employing this method, we examined diastereomer selectivity in the formation of 1″-OH-BF from BF racemate or enantiomers in four individual samples of human liver microsomes. Three different human liver microsomes showed a selectivity of 1″R-OH <1″S-OH for BF enantiomers, which was similar to that of recombinant CYP2D6 expressed in insect cell microsomes, whereas one human liver microsomal fraction yielded a selectivity of 1″R-OH > 1″S-OH for BF enantiomers, which was similar to those of recombinant CYP2C19 expressed in insect cell microsomes. Recombinant CYP1A2 and CYP3A4 showed a selectivity similar to that of CYP2D6, but their BF 1″-hydroxylase activities were much lower than those of CYP2D6. In inhibition studies, quinidine, a known CYP2D6 inhibitor, markedly inhibited BF 1″-hydroxylation in the fractions of human liver microsomes that showed the CYP2D6-type selectivity. Furthermore, omeprazole, a known CYP2C19 inhibitor, efficiently suppressed the formation of 1″-OH-BF diastereomers from BF in the microsomal fraction that showed the CYP2C19-type selectivity. From these results, we concluded that the diastereomer selectivity in the formation of 1″-OH-BF from BF differs between CYP2D6 and CYP2C19, both of which can be determinant enzymes in the diastereoselective 1″-hydroxylation of BF in human liver microsomes.

Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume303
Issue number1
DOIs
Publication statusPublished - Oct 2002

Fingerprint

Liver Microsomes
Cytochrome P-450 CYP2D6
Hydroxylation
bufuralol
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP1A2
Quinidine
Omeprazole
Microsomes
Insects
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology

Cite this

Narimatsu, S., Takemi, C., Tsuzuki, D., Kataoka, H., Yamamoto, S., Shimada, N., ... Gonzalez, F. J. (2002). Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 303(1), 172-178. https://doi.org/10.1124/jpet.102.036533

Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. / Narimatsu, Shizuo; Takemi, Chie; Tsuzuki, Daisuke; Kataoka, Hiroyuki; Yamamoto, Shigeo; Shimada, Noriaki; Suzuki, Satoshi; Satoh, Tetsuo; Meyer, Urs A.; Gonzalez, Frank J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 303, No. 1, 10.2002, p. 172-178.

Research output: Contribution to journalArticle

Narimatsu, S, Takemi, C, Tsuzuki, D, Kataoka, H, Yamamoto, S, Shimada, N, Suzuki, S, Satoh, T, Meyer, UA & Gonzalez, FJ 2002, 'Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes', Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 172-178. https://doi.org/10.1124/jpet.102.036533
Narimatsu, Shizuo ; Takemi, Chie ; Tsuzuki, Daisuke ; Kataoka, Hiroyuki ; Yamamoto, Shigeo ; Shimada, Noriaki ; Suzuki, Satoshi ; Satoh, Tetsuo ; Meyer, Urs A. ; Gonzalez, Frank J. / Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 303, No. 1. pp. 172-178.
@article{1f19565b313c4bc68e1e33ce302004c3,
title = "Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes",
abstract = "A new HPLC method was developed using a chiral column to efficiently separate four 1″-hydroxybufuralol (1″-OH-BF) diastereomers that are major metabolites of bufuralol (BF). Employing this method, we examined diastereomer selectivity in the formation of 1″-OH-BF from BF racemate or enantiomers in four individual samples of human liver microsomes. Three different human liver microsomes showed a selectivity of 1″R-OH <1″S-OH for BF enantiomers, which was similar to that of recombinant CYP2D6 expressed in insect cell microsomes, whereas one human liver microsomal fraction yielded a selectivity of 1″R-OH > 1″S-OH for BF enantiomers, which was similar to those of recombinant CYP2C19 expressed in insect cell microsomes. Recombinant CYP1A2 and CYP3A4 showed a selectivity similar to that of CYP2D6, but their BF 1″-hydroxylase activities were much lower than those of CYP2D6. In inhibition studies, quinidine, a known CYP2D6 inhibitor, markedly inhibited BF 1″-hydroxylation in the fractions of human liver microsomes that showed the CYP2D6-type selectivity. Furthermore, omeprazole, a known CYP2C19 inhibitor, efficiently suppressed the formation of 1″-OH-BF diastereomers from BF in the microsomal fraction that showed the CYP2C19-type selectivity. From these results, we concluded that the diastereomer selectivity in the formation of 1″-OH-BF from BF differs between CYP2D6 and CYP2C19, both of which can be determinant enzymes in the diastereoselective 1″-hydroxylation of BF in human liver microsomes.",
author = "Shizuo Narimatsu and Chie Takemi and Daisuke Tsuzuki and Hiroyuki Kataoka and Shigeo Yamamoto and Noriaki Shimada and Satoshi Suzuki and Tetsuo Satoh and Meyer, {Urs A.} and Gonzalez, {Frank J.}",
year = "2002",
month = "10",
doi = "10.1124/jpet.102.036533",
language = "English",
volume = "303",
pages = "172--178",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes

AU - Narimatsu, Shizuo

AU - Takemi, Chie

AU - Tsuzuki, Daisuke

AU - Kataoka, Hiroyuki

AU - Yamamoto, Shigeo

AU - Shimada, Noriaki

AU - Suzuki, Satoshi

AU - Satoh, Tetsuo

AU - Meyer, Urs A.

AU - Gonzalez, Frank J.

PY - 2002/10

Y1 - 2002/10

N2 - A new HPLC method was developed using a chiral column to efficiently separate four 1″-hydroxybufuralol (1″-OH-BF) diastereomers that are major metabolites of bufuralol (BF). Employing this method, we examined diastereomer selectivity in the formation of 1″-OH-BF from BF racemate or enantiomers in four individual samples of human liver microsomes. Three different human liver microsomes showed a selectivity of 1″R-OH <1″S-OH for BF enantiomers, which was similar to that of recombinant CYP2D6 expressed in insect cell microsomes, whereas one human liver microsomal fraction yielded a selectivity of 1″R-OH > 1″S-OH for BF enantiomers, which was similar to those of recombinant CYP2C19 expressed in insect cell microsomes. Recombinant CYP1A2 and CYP3A4 showed a selectivity similar to that of CYP2D6, but their BF 1″-hydroxylase activities were much lower than those of CYP2D6. In inhibition studies, quinidine, a known CYP2D6 inhibitor, markedly inhibited BF 1″-hydroxylation in the fractions of human liver microsomes that showed the CYP2D6-type selectivity. Furthermore, omeprazole, a known CYP2C19 inhibitor, efficiently suppressed the formation of 1″-OH-BF diastereomers from BF in the microsomal fraction that showed the CYP2C19-type selectivity. From these results, we concluded that the diastereomer selectivity in the formation of 1″-OH-BF from BF differs between CYP2D6 and CYP2C19, both of which can be determinant enzymes in the diastereoselective 1″-hydroxylation of BF in human liver microsomes.

AB - A new HPLC method was developed using a chiral column to efficiently separate four 1″-hydroxybufuralol (1″-OH-BF) diastereomers that are major metabolites of bufuralol (BF). Employing this method, we examined diastereomer selectivity in the formation of 1″-OH-BF from BF racemate or enantiomers in four individual samples of human liver microsomes. Three different human liver microsomes showed a selectivity of 1″R-OH <1″S-OH for BF enantiomers, which was similar to that of recombinant CYP2D6 expressed in insect cell microsomes, whereas one human liver microsomal fraction yielded a selectivity of 1″R-OH > 1″S-OH for BF enantiomers, which was similar to those of recombinant CYP2C19 expressed in insect cell microsomes. Recombinant CYP1A2 and CYP3A4 showed a selectivity similar to that of CYP2D6, but their BF 1″-hydroxylase activities were much lower than those of CYP2D6. In inhibition studies, quinidine, a known CYP2D6 inhibitor, markedly inhibited BF 1″-hydroxylation in the fractions of human liver microsomes that showed the CYP2D6-type selectivity. Furthermore, omeprazole, a known CYP2C19 inhibitor, efficiently suppressed the formation of 1″-OH-BF diastereomers from BF in the microsomal fraction that showed the CYP2C19-type selectivity. From these results, we concluded that the diastereomer selectivity in the formation of 1″-OH-BF from BF differs between CYP2D6 and CYP2C19, both of which can be determinant enzymes in the diastereoselective 1″-hydroxylation of BF in human liver microsomes.

UR - http://www.scopus.com/inward/record.url?scp=0036784537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036784537&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.036533

DO - 10.1124/jpet.102.036533

M3 - Article

C2 - 12235248

AN - SCOPUS:0036784537

VL - 303

SP - 172

EP - 178

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -